Denali Therapeutics Inc.
DNLI- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001714899
In the last 90 days, Denali Therapeutics Inc. insiders filed 0 open-market purchases and 4 sales; 294 institutions reported holding it in 13F filings for Q2 2026, worth $4.00B in total; no superinvestor holds it.
13F holders, Q2 2021
Institutional positions in Denali Therapeutics Inc. as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 210
- −7 vs. Q1 2021
- Shares held
- 80.6M
- +149.8K (+0.2%) vs. Q1 2021
- Total value
- $6.32B
- +$1.72B (+37.5%) vs. Q1 2021
- New holders
- 34
- 81 more added
- Sold out
- 41
- 59 more reduced
1 institution that held it in Q1 2021 haven't filed for Q2 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting DNLI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 294 | $4.00B |
| Q1 2026 | 269 | $2.82B |
| Q4 2025 | 250 | $2.50B |
| Q3 2025 | 240 | $1.97B |
| Q2 2025 | 231 | $1.93B |
| Q1 2025 | 222 | $1.85B |
| Q4 2024 | 224 | $2.61B |
| Q3 2024 | 217 | $3.69B |
| Q2 2024 | 203 | $2.88B |
| Q1 2024 | 211 | $2.51B |
| Q4 2023 | 209 | $2.47B |
| Q3 2023 | 195 | $2.24B |
| Q2 2023 | 203 | $3.18B |
| Q1 2023 | 202 | $2.49B |
| Q4 2022 | 199 | $2.94B |
| Q3 2022 | 200 | $2.84B |
| Q2 2022 | 188 | $2.73B |
| Q1 2022 | 190 | $2.79B |
| Q4 2021 | 213 | $3.80B |
| Q3 2021 | 214 | $4.28B |
| Q2 2021 | 210 | $6.32B |
| Q1 2021 | 218 | $4.60B |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding Denali Therapeutics Inc.; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| State Street Corp | 2,320,460 | $182.0M | 0.01% | +303,793+15.1% | Added |
| FMR LLC | 2,669,083 | $209.4M | 0.02% | −18,617−0.7% | Reduced |
| Flagship Pioneering Inc. | 2,730,263 | $214.2M | 2.74% | 00.0% | Unchanged |
| Gilder Gagnon Howe & Co LLC | 2,835,733 | $222.4M | 1.09% | −168,820−5.6% | Reduced |
| Temasek Holdings (Private) Ltd | 4,410,457 | $346.0M | 1.16% | 00.0% | Unchanged |
| Price T Rowe Associates Inc | 4,903,452 | $384.6M | 0.04% | −1,154,827−19.1% | Reduced |
| BlackRock Inc. | 7,036,041 | $551.9M | 0.02% | +471,589+7.2% | Added |
| Vanguard Group Inc | 7,644,130 | $599.6M | 0.01% | −522,320−6.4% | Reduced |
| Crestline Management, LP | 8,135,481 | $638.1M | 55.19% | −1,849,355−18.5% | Reduced |
| Baillie Gifford & Co | 15,147,613 | $1.19B | 0.58% | +2,152,416+16.6% | Added |
| IFP Advisors, Inc | 0 | $0 | 0.00% | −20−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −240,784−100.0% | Sold out |
| Caas Capital Management LP | 0 | $0 | 0.00% | −232,796−100.0% | Sold out |
| Hamilton Lane Advisors LLC | 0 | $0 | 0.00% | −97,370−100.0% | Sold out |
| Arrowstreet Capital, Limited Partnership | 0 | $0 | 0.00% | −85,607−100.0% | Sold out |
| Tudor Investment Corp Et Al | 0 | $0 | 0.00% | −39,106−100.0% | Sold out |
| Voloridge Investment Management, LLC | 0 | $0 | 0.00% | −27,958−100.0% | Sold out |
| Parallax Volatility Advisers, L.P. | 0 | $0 | 0.00% | −26,777−100.0% | Sold out |
| University of Texas/Texas Am Investment Managment Co | 0 | $0 | 0.00% | −23,629−100.0% | Sold out |
| Mackay Shields LLC | 0 | $0 | 0.00% | −22,400−100.0% | Sold out |
| Jefferies Group LLC | 0 | $0 | 0.00% | −21,100−100.0% | Sold out |
| Duality Advisers, LP | 0 | $0 | 0.00% | −19,642−100.0% | Sold out |
| Fred Alger Management, LLC | 0 | $0 | 0.00% | −16,634−100.0% | Sold out |
| Trexquant Investment LP | 0 | $0 | 0.00% | −16,192−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −14,300−100.0% | Sold out |
| AlphaCrest Capital Management LLC | 0 | $0 | 0.00% | −13,400−100.0% | Sold out |
| Ergoteles LLC | 0 | $0 | 0.00% | −10,300−100.0% | Sold out |
| Frontier Capital Management Co LLC | 0 | $0 | 0.00% | −7,742−100.0% | Sold out |
| Athanor Capital, LP | 0 | $0 | 0.00% | −6,709−100.0% | Sold out |
| Dynamic Technology Lab Private Ltd | 0 | $0 | 0.00% | −6,570−100.0% | Sold out |
| Tao Capital Management LP | 0 | $0 | 0.00% | −6,086−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −5,583−100.0% | Sold out |
| Y-Intercept (Hong Kong) Ltd | 0 | $0 | 0.00% | −4,886−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −3,683−100.0% | Sold out |
| FORA Capital, LLC | 0 | $0 | 0.00% | −2,020−100.0% | Sold out |
| Bank of Montreal | 0 | $0 | 0.00% | −1,885−100.0% | Sold out |
| Pacer Advisors, Inc. | 0 | $0 | 0.00% | −1,204−100.0% | Sold out |
| HM Payson & Co | 0 | $0 | 0.00% | −1,013−100.0% | Sold out |
| Walleye Trading LLC | 0 | $0 | 0.00% | −835−100.0% | Sold out |
| Lazard Asset Management LLC | 0 | $0 | 0.00% | −833−100.0% | Sold out |
| Cutler Group LP | 0 | $0 | 0.00% | −600−100.0% | Sold out |
| Bank Julius Baer & Co. Ltd, Zurich | 0 | $0 | 0.00% | −500−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −449−100.0% | Sold out |
| Ameritas Investment Company, LLC | 0 | $0 | 0.00% | −200−100.0% | Sold out |
| Sowell Financial Services LLC | 0 | $0 | 0.00% | −160−100.0% | Sold out |
| Exchange Traded Concepts, LLC | 0 | $0 | 0.00% | −125−100.0% | Sold out |
| Signaturefd, LLC | 0 | $0 | 0.00% | −67−100.0% | Sold out |
| Alpha DNA Investment Management LLC | 0 | $0 | 0.00% | −79−100.0% | Sold out |
| Lindbrook Capital, LLC | 0 | $0 | 0.00% | −34−100.0% | Sold out |
| Parallel Advisors, LLC | 0 | $0 | 0.00% | −12−100.0% | Sold out |
| Raffa Wealth Management, LLC | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Amundi Asset Management US, Inc. | – | – | – | – | Not filed |